

# Webcast: Life Sciences 2025 Outlook

## Webcast Series: Royalty Finance

Webcasts | March 12, 2025

---

The life sciences industry entered 2025 with a largely favorable set of catalysts, but also with some larger risks that will impact companies differently. Join our team of seasoned attorneys and industry leaders for part one of this webcast series, where we provide an integrated outlook on royalty finance in the life sciences, identifying trends and uncertainties that will shape the year ahead. For a copy of our full Life Sciences 2025 Outlook, [click here](#). Topics include:

### Related People

[Todd J. Trattner](#)

[Ryan A. Murr](#)

- Key development in 2024: continued growth in non-dilutive financing through debt, royalty financings and synthetic royalty financings, with a deeper pool of capital on the investor-side and a favorable macro-economic environment, provided that inflation does not return, and interest rates increase
- Expected impacts of a shifting geopolitical environment and regulatory landscape under the Trump administration

---

**MCLE CREDIT INFORMATION:** This program has been approved for credit by the New York State Continuing Legal Education Board for a maximum of 0.5 credit hour in the professional practice category. This course is approved for transitional and non-transitional credit. Gibson, Dunn & Crutcher LLP certifies this activity is approved for 0.5 hour of MCLE credit by the State Bar of California in the General Category. California attorneys may claim self-study credit for viewing the archived webcast. No certificate of attendance is required for self-study credit.

---

### PANELISTS:

- Todd Trattner (Gibson Dunn)
- Ryan Murr (Gibson Dunn)
- Doug Prescott (TD Cowen)

© 2025 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at [www.gibsondunn.com](http://www.gibsondunn.com). Attorney Advertising: These materials were prepared for general informational purposes only based on information available at the time of publication and are not intended as, do not constitute, and should not be relied upon as, legal advice or a legal opinion on any specific facts or circumstances. Gibson Dunn (and its affiliates, attorneys, and employees) shall not have any liability in connection with any use of these materials. The sharing of these materials does not establish an attorney-client relationship with the recipient and should not be relied upon as an alternative for advice from qualified counsel. Please note that facts and circumstances may vary, and prior results do not guarantee a similar outcome.

### Related Capabilities

[Life Sciences](#)